Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan

Friday, December 22, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has announced the opening of a Phase 1 therapeutic trial for non-small cell lung cancer (NSCLC) starting January 4, 2024. This trial aims to evaluate the efficacy of their drug targeting B7H3. The initiation of this trial marks a notable advancement in the company's clinical research efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Phase 1 trial for NSCLC is a significant step forward.
  • Initiation of the trial indicates progress in cancer treatment.
  • Positive clinical updates from Radiopharm Theranostics.

Full Press Release Details

• Announcements
• Price Sensitive , With Video
• December 22, 2023
ANNOUNCEMENT SUMMARY
Loading Viewer…

More Announcements & Updates

• Announcements
• October 22, 2022
• Announcements
• November 30, 2021
• Announcements
• November 30, 2021
• Announcements
• November 29, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the focus of the Phase 1 trial?

The trial focuses on treating non-small cell lung cancer (NSCLC) using a drug targeting B7H3.

When does the Phase 1 NSCLC trial start?

The Phase 1 trial is set to begin on January 4, 2024.

Who is conducting the NSCLC trial?

The trial is being conducted by Radiopharm Theranostics.

What is the significance of this trial?

This trial represents a significant advancement in Radiopharm's clinical research efforts.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics NSCLC B7H3 Phase 1 trial lung cancer
Last updated: Dec 22, 2023